Boehringer Ingelheim and NPO Petrovax Pharm, a leading Russian manufacturer of immunobiological medicines, announced that the commercial series of innovative thrombolytics will be launched onto the Russian market as early as this June. The agreement on localizing the full manufacturing cycle of advanced medicines for the treatment of cardiovascular diseases was signed on June 9, 2016. Localization has become a part of the integrated approach to reducing mortality from cardiovascular diseases, which brought together the efforts of public health care system, medical community, patient organizations, and businesses.
The project provides for the production of two thrombolytic medicines that represent the “gold standard” in the treatment of heart attacks and strokes. Their effectiveness and safety have been confirmed by numerous international clinical trials.
“Since its establishment, Petrovax Pharm is using its production capacity only for manufacturing the original medicinal products,” said Elena Arkhangelskaya, the President of Petrovax Pharm. “The company is focused on producing complex high-tech products demanded by Russian health care system. This is the reason why we are interested in localizing the products of Boehringer Ingelheim. Our localization project is unique not only in terms of technology but also in terms of implementation speed. We will implement it within a very short time and, by 2019, we expect to complete the localization of the full cycle.”